National Institute on Drug Abuse; Notice of Closed Meetings, 5795-5796 [2018-02566]

Download as PDF 5795 Federal Register / Vol. 83, No. 28 / Friday, February 9, 2018 / Notices Abstract: HRSA is requesting the Organ Procurement and Transplantation Network (OPTN) perform a federally sponsored data collection as part of a pilot project to monitor the testing of deceased potential donors possibly exposed to the Zika virus (ZIKV). The Zika Pilot Project will have a 12-month performance period enabling OPTN to develop a plan to collect data on ways for organ procurement organizations (OPOs) to deploy ZIKV donor screening tests of blood products. The testing is available under an investigational new drug application for use on a voluntary basis in the evaluation of deceased persons as potential solid organ donors. OPTN will conduct an analysis of the data collected under this project to determine the potential effect of making available screening tests for ZIKV, when appropriate, to improve transplant safety. OPTN will convene a group of stakeholders to provide guidance and monitor progress on the ZIKV pilot project. Need and Proposed Use of the Information: ZIKV is prevalent in several areas of the United States. Currently, there is not a ZIKV screening procedure for OPOs to implement during the organ allocation process. HRSA requested OPTN to conduct a pilot project to monitor the testing of deceased donors potentially exposed to ZIKV. The goals of the pilot project are to: • Collaborate with experts to define necessary data elements to understand the impact of ZIKV testing in deceased organ donors; • Deploy a data collection tool to a limited number of OPOs that agree to participate in the pilot project; and • Assess the ability of OPTN to respond to a public health situation by collecting data from impacted members of the transplant community to assess the national experience. Likely Respondents: Organ Procurement Organizations. Burden Statement: Burden in this context means the time expended by persons to generate, maintain, retain, disclose, or provide the information requested. This includes the time needed to review instructions; to develop, acquire, install, and utilize technology and systems for the purpose of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; to train personnel and to be able to respond to a collection of information; to search data sources; to complete and review the collection of information; and to transmit or otherwise disclose the information. The total annual burden hours estimated for this ICR are summarized in the table below. TOTAL ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Form name Number of responses per respondent Total responses Average burden per response (in hours) Total burden hours ZIKV Data Collection Tool ................................................... 20 167 3,340 .508 1,696.7 Total .............................................................................. 20 ........................ 3,340 ........................ 1,696.7 * Total number of responses determined by applying the percentage of OPOs participating to the total number of deceased donors in 2016. Based on OPTN Data as of 11/09/2017. ** Donors screened for ZIKV will be based on OPO specific screening criteria. HRSA specifically requests comments on: (1) The necessity and utility of the proposed information collection for the proper performance of the agency’s functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden. Amy McNulty, Acting Director, Division of the Executive Secretariat. 2018, 08:30 a.m. to January 22, 2018, 05:00 p.m., Hilton Garden Inn Bethesda, 7301 Waverly Street, Bethesda, MD 20814 which was published in the Federal Register on December 28, 2017, 82 FR 61577. This meeting is being amended to change the date from January 22, 2018 to February 23, 2018. The time has not changed. The meeting is closed to the public. Dated: February 5, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–02565 Filed 2–8–18; 8:45 am] [FR Doc. 2018–02586 Filed 2–8–18; 8:45 am] BILLING CODE 4140–01–P BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES sradovich on DSK3GMQ082PROD with NOTICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health National Eye Institute; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Eye Institute Special Emphasis Panel, January 22, VerDate Sep<11>2014 16:57 Feb 08, 2018 Jkt 244001 National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Multisite Clinical Trials. Date: February 16, 2018. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301–827–5820, hiromi.ono@nih.gov. E:\FR\FM\09FEN1.SGM 09FEN1 5796 Federal Register / Vol. 83, No. 28 / Friday, February 9, 2018 / Notices Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; R13 Conference Grant Review. Date: February 23, 2018. Time: 1:00 p.m. to 2:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Ivan K. Navarro, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892, 301–827–5833, ivan.navarro@ nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: February 5, 2018. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–02566 Filed 2–8–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY [Docket No. DHS–2018–0007] Homeland Security Science and Technology Advisory Committee Science and Technology Directorate, DHS. ACTION: Committee management; notice of open Federal Advisory Committee meeting. The Homeland Security Science and Technology Advisory Committee (HSSTAC) will meet via teleconference on Thursday, February 22, 2018. The meeting will be an open session. DATES: The HSSTAC teleconference meeting will take place Thursday, February 22, 2018 from 11:00 a.m. to 12:00 p.m. The meeting may close early if the committee has completed its business. SUMMARY: Members of the public may participate by teleconference but you must register. Please see the ‘‘REGISTRATION’’ section below. FOR FURTHER INFORMATION CONTACT: Michel Kareis, HSSTAC Designated Federal Official, S&T Interagency Office (IAO), STOP 0205, Department of Homeland Security, 245 Murray Lane, Washington, DC 20528–0205, 202–254– 8778 (Office), 202–254–6176 (Fax), HSSTAC@hq.dhs.gov (Email). SUPPLEMENTARY INFORMATION: sradovich on DSK3GMQ082PROD with NOTICES VerDate Sep<11>2014 16:57 Feb 08, 2018 Jkt 244001 Notice of this meeting is given under the Federal Advisory Committee Act (FACA), 5 U.S.C. Appendix (Pub. L. 92– 463). The committee addresses areas of interest and importance to the Under Secretary for Science and Technology (S&T), such as new developments in systems engineering, cyber-security, knowledge management and how best to leverage related technologies funded by other Federal agencies and by the private sector. It also advises the Under Secretary on policies, management processes, and organizational constructs as needed. II. Registration To pre-register for the teleconference please send an email to: HSSTAC@ hq.dhs.gov with the following subject line: RSVP to HSSTAC meeting. The email should include the name(s), title, organization/affiliation, email address, and telephone number of those interested in attending. You must RSVP by February 20, 2018. For information on services for individuals with disabilities or to request special assistance at the meeting, please contact Michel Kareis as soon as possible. Her contact information is listed above in the FOR FURTHER INFORMATION CONTACT section. III. Public Comment AGENCY: ADDRESSES: I. Background At the end of the open session, there will be a period for oral statements. Please note that the comments period may end before the time indicated, following the last call for oral statements. To register as a speaker, contact the person listed in the FOR FURTHER INFORMATION CONTACT section. To facilitate public participation, we invite public comment on the issues to be considered by the committee as listed in the ‘‘Agenda’’ below. Anyone is permitted to submit comments at any time, including orally at the meeting. However, those who would like their comments reviewed by committee members prior to the meeting must submit them in written form no later than February 19, 2018. Please include the docket number (DHS–2018–0007) and submit via one of the following methods: • Federal eRulemaking Portal: https:// www.regulations.gov. Follow the instructions for submitting comments. • Email: hsstac@hq.dhs.gov. Include the docket number in the subject line of the message. • Fax: 202–254–6176. • Mail: Michel Kareis, HSSTAC Designated Federal Official, S&T IAO, STOP 0205, Department of Homeland PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 Security, 245 Murray Lane, Washington, DC 20528–0205. Instructions: All submissions received must include the words ‘‘Department of Homeland Security’’ and the docket number. Comments received will be posted without alteration at https:// www.regulations.gov. Docket: For access to the docket to read the background documents or comments received by the HSSTAC, go to https://www.regulations.gov and enter the docket number into the search function: DHS–2018–0007. Agenda: The session will begin with remarks from the Designated Federal Official, Michel Kareis, and the Committee Chair, Dr. Vincent Chan. Next the Social Media Working Group for Emergency Services and Disaster Management Subcommittee will discuss their report, ‘‘Countering Misinformation, Rumors, and Fake News on Social Media in Emergencies and Disasters’’, followed by a full committee vote to accept the report. To request a copy of the report prior to the meeting please send an email to: hsstac@hq.dhs.gov. The last item on the agenda will be the announcement of a new subcommittee on Systems Engineering Feasibility. A public comment period will be held at the end of the open session. Dated: February 6, 2018. Michel Kareis, Designated Federal Official for the HSSTAC. [FR Doc. 2018–02665 Filed 2–8–18; 8:45 am] BILLING CODE 9110–9F–P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR–6035–N–03] Notice of Regulatory Waiver Requests Granted for the Third Quarter of Calendar Year 2017 AGENCY: Office of the General Counsel, HUD. ACTION: Notice. Section 106 of the Department of Housing and Urban Development Reform Act of 1989 (the HUD Reform Act) requires HUD to publish quarterly Federal Register notices of all regulatory waivers that HUD has approved. Each notice covers the quarterly period since the previous Federal Register notice. The purpose of this notice is to comply with the requirements of section 106 of the HUD Reform Act. This notice contains a list of regulatory waivers granted by HUD during the period beginning on July 1, SUMMARY: E:\FR\FM\09FEN1.SGM 09FEN1

Agencies

[Federal Register Volume 83, Number 28 (Friday, February 9, 2018)]
[Notices]
[Pages 5795-5796]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-02566]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Multi-site Clinical Trials.
    Date: February 16, 2018.
    Time: 1:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Policy and Review, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive 
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820, 
[email protected].


[[Page 5796]]


    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; R13 Conference Grant Review.
    Date: February 23, 2018.
    Time: 1:00 p.m. to 2:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Ivan K. Navarro, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892, 
301-827-5833, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: February 5, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-02566 Filed 2-8-18; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.